---
layout: post
title: "General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:00:38 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-19410
original_published: 2022-09-08 00:00:00 +0000
significance: 8.00
---

# General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** September 08, 2022 00:00 UTC
**Document Number:** 2022-19410

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products," replacing the December 2014 draft guidance of the same name. This draft guidance, once finalized, will assist sponsors of investigational new drug applications (INDs) and applicants of new drug applications (NDAs), biologics license applications (BLAs), and supplements to such applications, who are planning to conduct clinical studies in pediatric populations. In addition, this draft guidance, once finalized, will assist investigators in the design and planning of, and Institutional Review Boards in the assessment of, clinical studies in pediatric populations.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/09/08/2022-19410/general-clinical-pharmacology-considerations-for-pediatric-studies-of-drugs-including-biological)
- API: https://www.federalregister.gov/api/v1/documents/2022-19410

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
